J., Y., S., T., J., L., D., D., S., P., J., P., . . . H., L. (2017). A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study.
Chicago Style CitationJ., Yi, Thongprasert S., Lee J., Doval D., Park S., Park J., Park Y., Kang W., and Lim H. A Phase II Study of Sunitinib As a Second-line Treatment in Advanced Biliary Tract Carcinoma: A Multicentre, Multinational Study. 2017.
MLA引文J., Yi, et al. A Phase II Study of Sunitinib As a Second-line Treatment in Advanced Biliary Tract Carcinoma: A Multicentre, Multinational Study. 2017.
警告:這些引文格式不一定是100%准確.